Mayo Clinic
The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.
Demonstrating that ACE inhibitor therapy with lisinopril lowers hemoglobin, hematocrit, and erythropoietin levels could introduce a novel therapeutic approach for the management of secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis, potentially reducing reliance on repeated phlebotomies and lowering thrombotic risk.
Inclusion Criteria: * Hemoglobin in Men: \>16.5 g/dL (10.3 mmol/L). * Hemoglobin in Women \>16.0 g/dL (10.0 mmol/L). * BMI 18-40 kg/m2. Exclusion Criteria: * Positive JAK2 gene linked to Polycythemia Vera. * Current smoker or previous heavy smoker (\>15 pack years) who quit less than 12 months prior to enrollment. * Resting SpO₂ ≤ 94% on room air. * Current or recent (within the past 6 months) use of testosterone or androgen supplementation. * Any confounding respiratory or renal disease, including diagnosed or suspected sleep apnea, or stage 3 and up of chronic kidney disease. * Any confou…
Subjects will be treated with Lisinopril in three phases: Phase 1: Baseline-3 weeks: 2.5 mg dose Phase 2: Weeks 4 - 7: 5 mg dose (2 x 2.5mg tablets) Phase 3: Weeks 8-12: 10 mg dose (4 x 2.5 mg tablets)
Arctuva estimate
Verify or correct the compensation shown for this listing.